Replies to post #3148 on Cassava Sciences Inc (SAVA)

[FooBarAndGrill]

The phone and email records from this 3-week period are key. Do they exist?

a council of senior agency officials met to review Aduhelm, also called aducanumab, and resoundingly agreed there wasn’t enough evidence that it worked

But just three weeks after that meeting, in April 2021, the F.D.A. told Biogen it was now considering Aduhelm for “accelerated approval,”